<DOC>
	<DOCNO>NCT01928381</DOCNO>
	<brief_summary>This 2-part study . In Part 1 study , subject undergo pain report train program painful stimulus apply subject 's hand , subject ask report painful stimulus . Over course pain training session , feedback provide subject accurately report degree pain , relative amount pressure stimulus apply evoke pain . Those subject adequate pain reporting ability ask continue Part 2 study 3 different blind study drug administer subject , crossover design compare whether study drug improve pain associate diabetic neuropathy .</brief_summary>
	<brief_title>Safety , Tolerability Preliminary Efficacy AZD5213 Combination With Pregabalin Subjects With PDN Good Pain Reporting Ability</brief_title>
	<detailed_description>This multi-center , randomize , two-part study adult ( age 18-75 year ) Painful Diabetic Neuropathy ( PDN ) . In Part 1 study , eligible subject enter 4-week Pain Training Period . During Pain Training Period , subject receive three weekly in-clinic training session use repeat rating experimental pressure pain stimulus . Subjects receive feedback training evaluate pain-reporting ability in-clinic session . Subjects acceptable pain-reporting ability conclusion Pain Training Period eligible enter Part 2 study . Subjects unacceptable pain-reporting ability conclusion Pain Training Period discontinue study . Part 2 study consist three consecutive double-blind crossover period . Each crossover period include 31 day double-blind treatment . A follow-up visit occur 14 Â± 7 day last dose study medication . One three treatment ( placebo , pregabalin , pregabalin + AZD5213 ) administer crossover treatment period , determine randomly assign treatment sequence . Approximately 65 subject screen Part 1 study , order randomize approximately 32 subject Part 2 study .</detailed_description>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>1 . Male female , age 18 75 year , inclusive , Screen . 2 . Subjects must provide informed consent accordance local regulation conduct studyrelated procedure . The informed consent reflect protocol stipulation concern use contraception . 3 . Diagnosis Type 1 Type 2 diabetes mellitus least 1 year prior Screen . 4 . Diabetesrelated painful neuropathy least 6 month prior Screen . 5 . Pain begin foot symmetric nearly symmetric . 6 . Diabetes clinically stable least 2 month prior Screen , Screen baseline ( Day 35 ) . 7 . At Screen baseline , score least 4 Item 5 ( `` average pain '' ) modify Brief Pain Inventory patient painful diabetic peripheral neuropathy ( BPIDPN ) . 8 . Able participate schedule evaluation complete require test procedure . 9 . In opinion investigator , subject must consider likely comply study protocol high probability complete study . 1 . Known suspected hypersensitivity pregabalin . 2 . Clinically important illness infection ( e.g. , chronic , persistent , acute infection ) within 30 day prior screen screen adn baseline . 3 . Presence psychiatric neurologic disorder disorder symptom , , judgement investigator , disorder symptom likely confound interpretation drug effect affect subject 's ability complete study . Any clinically important abnormality , determine investigator Screen baseline , physical neurologic examination , vital sign , ECG , clinical laboratory test result could detrimental subject , could affect subject 's ability complete study . 4 . Initiation change intensity frequency nonpharmacologic therapy PDN , include psychotherapy , physical therapy , massage , acupuncture , acupressure , chiropractic care , within 3 month prior baseline ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>